EIF2AK3 and tauopathy: Over the past decade, histological evidence of UPR activation, particularly the detection of phosphorylated PERK (PERK-P) and eIF2α-P, has increasingly been reported in post-mortem brain tissue from patients with Alzheimer’s disease, ALS, Parkinson’s disease, and also in the tauopathies progressive supranuclear palsy and frontotemporal dementia (Hoozemans et al., 2007, 2009; Atkin et al., 2008; Stutzbach et al., 2013).